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The overall TB prevalence in Cambodia is 
extremely high. In 2007, the estimated 
prevalence of all forms of TB was 664 per 
100 000 population, with a smear positive 
incidence of 219 per 100 000 making Cambodia 
among the 22 highest burden countries for TB 
in the world.  The TB mortality rate was 90 
per 100, 000 population. 
A survey was conducted by CENAT in 2001-2002 
in Cambodia and revealed a prevalence of
3.1% MDR-TB among previously treated cases. 
Treatment outcomes of drug-resistant tuber-
culosis (DR-TB) are known to be signiﬁ  cantly 
worse than in ﬁ   rst-line treated TB patients. 
Moreover, outbreaks of DRTB in populations 
cause alarmingly high mortality rates that require 
a prompt and coordinated response by health 
oﬃ   cials and health-care providers.
 MSF has been operating a Chronic Diseases 
Clinic in Donkeo Referral Hospital, Takeo Province 
(with 199,424 inhabitants), since 2003. The clinic 
has oﬀ  ered comprehensive care and treatment 
to patients with HIV/AIDS, diabetes and 
hypertension. 
At the same time MSF became an active 
member of the Multi-Drug Resistant Tuberculosis 
Technical Working Group (TWG), based at the 
National TB Program, CENAT. MSF-Belgium and 
MSF-France, as well as CHC, a local NGO partner, 
greatly contributed to the establishment of 
this working group and received encouraging 
comments for bringing to the group technical 
expertise, as well as ﬁ  eld experience, from the 
ﬁ  rst treatment DR-TB programs in the country. 
I discovered that I had TB 18 years ago. Back then I was a soldier ﬁ  ghting against the Khmer Rouge 
and often had to go to the jungle towards the Thai border. This meant that I could not take my 
medication correctly and would interrupt the treatment before I got cured. It was also very 
expensive for me to buy the medication. I feel that this is my last chance to get well. 
P. V. 48 years old, Takeo
DR-TB in Cambodia and 
MSF’s involvement
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Project Description
Project location
Takeo province (3,563 square kilometers) is 
located in the south of Cambodia, bordering on 
Kandal, Kampong Speu and Kampot provinces 
and to the south with Vietnam. The current 
population is about 924,800 or 6.4% of the 
country’s total (14,363,519 in 2007). The popula-
tion density is 259.5 people per square kilometer.
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Project Objectives
Overall objective:
The overall objective of the project was to 
provide quality care to all patients suﬀ  ering
from DR-TB in Takeo province and to develop 
a model of care that would be applicable to 
other similar settings .
Before I was treated by MSF, I was given treatment six times. I bought drugs myself and spent a 
lot of money, but I kept on coughing blood. Now that I feel better I want to look for a job, perhaps 
as a mototaxi-driver. When I was sick, my daughter and her husband supported me, but I want to 
be able to support myself. However I am very worried that I will start coughing blood again if I take 
a job that is too exhausting. 
M.S., 55 years, Takeo
Takeo Province
Operational Districts and Health Centers7
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Speciﬁ  c objectives included:
1.  to improve the diagnosis of DR-TB 
2.  to improve treatment outcomes 
3. to decrease DR-TB transmission in the 
community
Case ﬁ  nding strategy
The aim of the case ﬁ   nding strategy was to
identify patients with DR-TB and to initiate 
adequate treatment in a timely manner. Timely 
identiﬁ  cation and prompt initiation of treatment
prevent acquisition of further resistance, 
progression to permanent lung damage and 
spread of the disease to others.
Only patients who were confirmed smear
positive BK with the following criteria were sent 
for culture and DST:
1.  patients failing Cat 2 or known as chronic 
cases
2. patients with smear positive TB entering 
Cat 2 regardless of the previous TB history 
(Cat 1 failure; Defaulter; Relapse, etc…); 
3. close contacts of MDR-TB smear positive 
patients 
The selection of patients eligible for DR-TB case 
ﬁ  nding was done in two ways:
1- through consultation of the TB register 
of patients registered since 2006 (active 
case ﬁ  nding)
2-  through referral of suspected patients 
detected by TB staﬀ   (passive case ﬁ  nding)
To conﬁ  rm the diagnosis of DRTB, smear sputum 
positive specimens were sent to Pasteur Institute 
in Phnom Penh for standard culture and Drug 
Susceptibility Testing (DST). If the culture was 
positive, then DST for 1st line anti-TB drugs was 
done at Pasteur and DST for 2nd line TB-drugs was 
done in Supra National Reference Laboratory 
in Hong Kong, for all MDR-TB cases. Growth 
detection and identiﬁ  cation of M. tuberculosis 
took on average 3–8 weeks and DST of an M. 
tuberculosis isolate took additional 2–4 weeks. 
The costs for culture and DST for 1st and 2nd line 
were 48 US$ and 430 US$ respectively.
The ﬁ  nal responsibility for enrolment of patients 
to MDR-TB treatment (DOTS plus program) 
was with the physician in charge for the TB 
ward at Donkeo referral hospital in cooperation 
with the MSF Medical doctor. 
Niklas Bergstrand8
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Treatment strategy
All patients found to have DR-TB, were initially 
started on a standardized treatment regimen 
that was then modiﬁ   ed to an individualized 
treatment regimen based on the patient’s 
DST results. Every treatment regimen initially 
consisted of at least four drugs that were likely 
to be eﬀ  ective. The dosage was determined by 
body weight. Eﬀ   orts were made to recognize 
and treat adverse drug eﬀ   ects in order to 
minimize the risk of treatment interruptions 
and prevent increased morbidity and mortality. 
An injectable agent (an aminoglycoside or 
capreomycin) was used for a minimum of six 
months (intensive phase) and at least four months 
past culture conversion. The minimum length of 
treatment was 18 months (continuation phase) 
after culture conversion. 
Drugs used by MSF-B included: Pyrazinamide 
(Z), Capreomycine (Cm), Levoﬂ  oxacin  (Lfx), 
Ethionamide (Eto), Cycloserin (CS) and PAS Paser 
(PAS). When second line resistance results 
became available, often up to two months into 
treatment, the treatment regimen was modiﬁ  ed 
to provide at least three drugs to which the 
infecting strain was found to be susceptible. 
Case holding strategy
A case presentation for each patient was 
organized before treatment initiation in order 
to discuss the medical history, review baseline 
lab results and other investigations, plan a 
treatment regimen, and identify any other special 
problems. These case discussions involved the 
MDR-TB doctors, TB nurses, counselors, social 
workers, and the project coordinator.
At the beginning of the program in 2007,
patients were hospitalized until smear 
conversion occurred. DOT was performed twice 
a day, six days per week by health staﬀ   in the TB 
ward and the TB doctor examined patients daily. 
Later in the program (2008) the time of 
hospitalization was reduced. Patients were then 
treated on ambulatory basis with monthly visits 
to the hospital for medical follow up. Treatment 
was taken at home by directly observed the
rapy (DOT) with three DOT watchers for each 
patient. The ﬁ   rst DOT watcher was a health 
professional who gave the prescribed medicines 
in the morning (injection and pills), and the 2nd 
and 3rd DOT watchers were villagers in the same 
Niklas Bergstrand
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community who volunteered to give medicines 
every evening. The DOT Watchers had a one-day 
training on TB/MDR drugs, doses and 
identification   of adverse events and were 
supervised by the MSF TB nurse and by the 1st 
DOT Watcher. 
Long hospitalization was never well accepted by 
patients who complained of isolation, boredom, 
homesickness and loneliness. It was found that 
drop-out rates were higher in the hospitalization 
phase than in the ambulatory phase.
Patient support and counseling
Treatment for DR-TB is long and diﬃ   cult  for 
patients. Many of the second-line anti-
tuberculosis drugs have signiﬁ  cant side eﬀ  ects. 
Some are common and, although debilitating, 
are relatively manageable, such as nausea and 
vomiting, while others are more severe and 
lifelong, such as deafness. Taking these drugs 
continuously for up to two years requires an 
enormous commitment from patients and their 
families. Supporting patients through education 
and counseling is of paramount importance 
in improving adherence to treatment and 
reducing default from treatment.
In Takeo, DR-TB patients and their care givers 
were oﬀ  ered counseling on the diagnosis day by 
a dedicated MSF DR-TB counselor supported 
by the TB Nurse supervisor. 
The aims of this counseling session were 
threefold:
1. to educate patients and families about
DR-TB and its treatment
2.  to assess the risk of transmission of DR-TB 
in the household and develop strategies
to minimize this risk
3.  to counsel household members and close 
contacts about the need for screening 
other family members 
The DR-TB counselor was always available 
to In addition, the DR-TB counselor was always 
available to counsel patients who were having 
diﬃ     culties adhering to treatment or who had 
missed clinic appointments. 
A comprehensive guideline for the counseling 
of DR-TB patients was soon developed by the 
MSF team as it was found that there was a lack of 
speciﬁ  c material and a protocol for the support
of patients with such a long and challenging 
treatment. The guidelines were shared with all 
partners involved in DRTB care in the country. 
Home Visits
Home visits were made by counselors and nurse 
supervisors at least once a month to provide 
medical follow up, emotional support to improve 
adherence and advice on infection control 
measures. During the visit the team also 
supervised and coached the DOT Watchers, 
and supplied drugs and medical materials. 
The medication that I take makes my eyes blurry. Sometimes I have trouble ﬁ  nding my way back 
to my house, so the neighbours will have to help me. I wish that my family would support me more, 
and I often feel lonely. But I am happy that there are neighbours who come every day to help me 
take my medication.
T.P., 60 years old, Takeo
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Treatment follow up and 
monitoring
Patients underwent an extensive evaluation 
before treatment initiation that included the 
following medical review and tests performed
by MoH/MSF-B TB doctors or nurses:
  sputum smear microscopy, culture and
DST to both ﬁ  rst and second-line drugs
  TB disease and treatment history
   past medical history
  documentation of suspected MDR-TB 
contacts
 physical  examination
 chest  radiograph 
 lab  tests
 psychiatric  evaluation 
During the hospitalization phase the MoH/MSF-B 
attending physician saw the patient on a daily 
basis. In the continuation phase the patient 
was seen as often as needed but at least once 
a month. Patients were monitored closely for 
signs of adverse events and for treatment failure. 
The timely and appropriate management of 
side eﬀ  ects was considered critical to treatment 
adherence. Special attention was put at each 
visit to evaluate for: 
 respiratory  distress 
  GI intolerance of medications 
  progression of hearing loss or tinnitus
  depression or psychotic symptoms. 
At each visit, a physical exam was done and 
lab tests were prescribed according to a written 
protocol.
This is the ﬁ  fth time that I am on treatment. Sometimes I feel that I don’t want to live anymore, 
because the side eﬀ  ects are so strong. I can’t eat my rice, and ﬁ  nd it diﬃ   cult to hold or carry things. 
When it gets really bad, I want to stop taking the medication. But my wife tells me to continue 
and really supports me. God bless me. 
Y. H., 66 years old, Takeo
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Nutritional support
IIn addition to causing malnutrition, DR-TB can 
be exacerbated by poor nutritional status. 
Thus, without nutritional support, patients 
can become enmeshed in a vicious cycle 
of   malnutrition and disease. The second-line 
antituberculosis medications can also decrease 
appetite, making adequate nutrition a greater 
challenge. 
For relatively non-malnourished patients, 
general and therapeutic food items were 
provided by MSF-B social workers to encourage 
the patients to have a balanced nutritional diet.
For malnourished patients, therapeutic foods 
(Plumpy’nut, BP-100, Soy Milk) were provided by 
MSF-B social workers under close follow up. 
Infection Control
Reducing the risk of transmission of drug-
resistant strains of TB in both health care 
facilities and at home is a vital concern. Infection 
control (including administrative, environmental, 
and personal protection measures) is therefore 
important to implement in patients’ homes, in 
health care facilities, and in the community at 
large.
The implementation of the IC measures included:
 improvement of natural ventilation in 
the hospital and houses 
 use of respiratory protectors, N95, by 
the health professionals 
  provision of surgical masks for all clients
sitting in waiting areas
During the hospitalization phase, patients and 
family received infection control health education 
before and during the treatment. Masks were 
provided to all patients, staﬀ  , and care takers. 
During the ambulatory phase, a patient-centered 
approach to DR-TB treatment allowed patients to 
be in their own homes and, as much as possible, 
resume a normal, autonomous life. In order to 
minimize the risk to other household members, 
an initial home assessment was conducted which 
considered the vulnerabilities of household 
members – young children, people with HIV and 
other chronic illnesses, along with an assessment 
of space available and ventilation in the home. 
From this, a risk-reduction plan was drawn up 
that included education about TB transmission, 
the need for cough hygiene, separate sleeping 
arrangements for the patient and strategies 
to reduce contact with vulnerable household 
members. Paper masks were also distributed to 
the patients.
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Program Outcomes
DST results for conﬁ  rmed MTB
DST revealed that 65% of patients were susceptible to ﬁ   rst line TB drugs, while 24% 
suﬀ   ered from MDR-TB, 9% from MonoDR-TB and 2% from PDR-TB. The high susceptibility
of MTB to ﬁ   rst line drugs was likely due to the low prevalence of MDR-TB among patients 
previously treated and the wide inclusion criteria.
24%
2%
9%
65%
0%
10%
20%
30%
40%
50%
60%
70%
MDR-TB PDR-TB MonoDR-TBS u s c e p t i b le
DST Result of MTB
Early outcomes for DR-TB patients diagnosed between 
April 2007 and April 2009 in Takeo
13 still receiving 
treatment
12.5% treatment 
default
2 defaulted 
treatment
6% total mortality
1died during 
treatment
16 started DR-TB 
treatment (94%)
1 not started on 
treatment (6%) (excluded)
17 DR-TB Diagnosed 
April 2007-April 2009
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Eight patients had their treatment regimens modiﬁ  ed. Reasons  for modiﬁ  cation of the regimen
included:
  severe side eﬀ  ects   lack of ancillary drugs
 drug  toxicity   second line DST results
 drug  intolerance   no clinical  improvement and suspicion of treatment failure
 
100% 100%
37.50%
14% 12.50% 7% 7%
0%
20%
40%
60%
80%
100%
120%
GIT disturbance
Arthralgia
Headache(Cs)
Ototoxicity
Psycho (Cs)
Liver toxicity
Reaction to PAS
Side effects with DR-TB treatment
The side eﬀ   ects from my medication are so strong that I cannot do anything until 1-2 PM. 
I vomit every morning, and have strong headaches and diarrhoea. I try to get on with my normal life 
but the medicine makes me feel very weak, and I sometimes have diﬃ   culties even standing up. 
My life has really changed a lot since I started taking this medication. 
Y. C., 48 years old, Takeo
All DR-TB program activities were successfully handed over to CHC, CENAT, and MoH in Takeo 
in April 2009.
Hand over of DR-TB activities
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Challenges and Lessons 
Learned
  Reliable DST, access to a quality controlled laboratory and a short delay between specimen 
collection and DST results are important factors for adequate patient management
  Long hospitalization was not well accepted by patients 
  Managing side eﬀ  ects was challenging for clinicians 
  Cold chain requirements need to be checked before shipping samples and before supplying 
facilities and homes with cold chain drugs 
  Intensive and supporting counseling, including emotional and social support are paramount 
for patient empowerment and treatment adherence 
  Infection control measures, especially administrative ones, are challenging to maintain.
Recommendations
  New, rapid diagnostics should be introduced as soon as possible to ensure early detection 
of DR-TB
  Hospitalization should be as short as possible 
  Training of clinicians on early recognition and management of side eﬀ  ects should be continuous 
  An expanded formulary of auxiliary drugs should be readily available
  The cold chain should be in place for sample transportation and drug supply
  Patient and family counseling should be introduced at the earliest possible time in  MDR-TB 
programs. 
  One person should be in charge of supervising infection control measures in each health 
facility. Attention should be given to the care takers who tend to stay with the patients in 
the same wardroom, in a supportive and compassionate manner.
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